All Stories

  1. T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation
  2. A CSF NPTX2-based residual metric captures prognostic heterogeneity within a proposed compensatory framework in prodromal Alzheimer’s disease
  3. Structural MRI signature predicts tau staging in Alzheimer's disease
  4. Neurotransmitter landscape and neurodegeneration patterns in Alzheimer’s Disease
  5. Motor, Extrapyramidal, and Cognitive Involvement in RFC1 Disease
  6. Frailty in early Alzheimer's disease: Complementary clinical value and prognostic significance in biomarker-defined mild cognitive impairment due to Alzheimer's disease
  7. [ 18 F]Fluorodeoxyglucose positron emission tomography ([ 18 F ] ...
  8. Abnormal Resting-State EEG delta and alpha rhythms in Huntington’s and Alzheimer’s Diseases: An exploratory study
  9. Exploring the spatial covariance of cerebral vascular density and amyloid burden in Alzheimer's disease
  10. Glymphatic clearance as revealed by diffusion tensor imaging along the perivascular space (DTI‐ALPS) is associated with Alzheimer's disease neuropathology and periodic rsEEG alpha rhythms in mild cognitive impairment participants
  11. Presynaptic dopaminergic imaging as a neurodegeneration staging biomarker in the alpha-synucleinopathy continuum
  12. The Inflammatory Side of Iatrogenic Cerebral Amyloid Angiopathy: Rethinking Therapeutic Opportunities
  13. Periodic and Aperiodic Electroencephalographic Rhythms During Vigilance Transitions in Alzheimer's Disease Mild Cognitive Impairment
  14. Delphi consensus guidelines for the use of striatal dopaminergic imaging and cardiac metaiodobenzylguanidine (MIBG) scintigraphy for the diagnosis of dementia and mild cognitive impairment with Lewy bodies
  15. Predicting epilepsy after new onset refractory status epilepticus due to autoimmune encephalitis: The  DAME  score
  16. MRI susceptibility map weighted imaging (SMWI) as a neurodegeneration biomarker in the prodromal to overt alpha-synucleinopathy continuum
  17. Smartphone-based prediction of dopaminergic deficit in prodromal and manifest Parkinson’s disease
  18. Cerebrospinal fluid NPTX2 and [18F]FDG PET track serotonergic vulnerability to neurodegeneration in prodromal Alzheimer’s disease
  19. Uncovering Clinical and Functional Neuroimaging Characteristics of Overt Stage Phenotypes Within the α-Synucleinopathy Spectrum
  20. Correction: Magnetic susceptibility components reveal different aspects of neurodegeneration in alpha-synucleinopathies
  21. Cerebrospinal Fluid Biomarkers Profiling in Cerebral Amyloid Angiopathy and Relationship With Disease Phenotypes
  22. Clinical Pathways for Diagnosing Neurocognitive Disorders: Insights From Process Mining a Memory Clinic Cohort
  23. Rituximab retreatment guided by CD27+ B-cell count vs. clinical relapse in anti-MAG polyneuropathy: a cost-effective approach with lower cumulative doses
  24. Longitudinal changes in [18F]FDG PET brain metabolism as a prognostic marker in autoimmune encephalitis
  25. [18F]FDG PET metabolic correlates of cerebrospinal fluid TAR DNA-binding protein 43 in prodromal Alzheimer's disease
  26. The compensatory effect of education as revealed by resting-state electroencephalographic alpha rhythms in patients with dementia due to Parkinson’s disease: findings from an exploratory study
  27. Neuropsychological and clinical variables associated with cognitive trajectories in patients with Alzheimer's disease
  28. Clinical and metabolic profiles in behavioural frontotemporal dementia: Impact of age at onset
  29. The Many Faces of REM Sleep Behavior Disorder. Providing Evidence for a New Lexicon
  30. Abnormal electroencephalographic rhythms from quiet wakefulness to light sleep in Alzheimer’s disease patients with mild cognitive impairment
  31. Resting-state electroencephalographic rhythms depend on sex in patients with dementia due to Parkinson's and Lewy Body diseases: An exploratory study
  32. Magnetic susceptibility components reveal different aspects of neurodegeneration in alpha-synucleinopathies
  33. Resting-State EEG Alpha Rhythms Are Related to CSF Tau Biomarkers in Prodromal Alzheimer’s Disease
  34. CSF IL-6, GDF-15, GFAP and NfL levels in early Alzheimer disease: a pilot study
  35. Role of Blood P-Tau Isoforms (181, 217, 231) in Predicting Conversion from MCI to Dementia Due to Alzheimer’s Disease: A Review and Meta-Analysis
  36. Clinical and biological underpinnings of longitudinal atrophy pattern progression in Alzheimer's disease
  37. Investigating interleukin-8 in Alzheimer's disease: A comprehensive review
  38. Relationship between Posterior Resting-State Electroencephalographic Alpha Rhythms and Cerebrospinal Fluid Biomarkers of Neuropathology in Patients with Alzheimer’s Disease Mild Cognitive Impairment
  39. Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [18F]FDG-PET study
  40. Anti-LGI1 encephalitis and Langerhans cell histiocytosis: Two associated entities? A case report
  41. Toward Quantitative Neurology: Sensors to Assess Motor Deficits in Dementia
  42. FDG-PET and ASL MRI identify largely overlapping hypermetabolic and hyperperfusion changes in limbic autoimmune encephalitis
  43. Metabolic and dopaminergic correlates of intellectual enrichment in de-novo Parkinson's disease patients
  44. Limbic Network Derangement Mediates Unawareness of Apathy in Mild Cognitive Impairment due to Alzheimer’s Disease: Clues from [18F]FDG PET Voxel-Wise Analysis
  45. Clinical versus biomarker-based diagnosis of neurocognitive disorders – Authors' reply
  46. Clinical and diagnostic implications of Alzheimer’s disease copathology in Lewy body disease
  47. Resting state electroencephalographic alpha rhythms are sensitive to Alzheimer’s disease mild cognitive impairment progression at a 6-month follow-up
  48. Ma2 antibody‐associated limbic encephalitis: The early etiology treatment may modify the disease clinical trajectory
  49. Autoimmune encephalitis: what the radiologist needs to know
  50. Diagnostic and prognostic value of dual-point amyloid PET in Alzheimer’s disease (AD) mimickers
  51. Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy
  52. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
  53. Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review
  54. Tracking the progression of Alzheimer's disease: Insights from metabolic patterns of SOMI stages
  55. Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when Occam razor is a double-edged sword
  56. Alzheimer’s disease (AD) co-pathology in dementia with Lewy bodies (DLB): implications in the disease modification era
  57. COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain–Barré syndrome
  58. Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease
  59. Sex differences in brain atrophy in dementia with Lewy bodies
  60. Relationship between default mode network and resting-state electroencephalographic alpha rhythms in cognitively unimpaired seniors and patients with dementia due to Alzheimer’s disease
  61. Editorial: CSF and blood biomarkers in COVID-19 and other neuroinfectious diseases
  62. CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease
  63. Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort
  64. Discrepancy Between Patient and Caregiver Estimate of Apathy Predicts Dementia in Patients with Amnestic Mild Cognitive Impairment
  65. Right posterior hypometabolism in Pisa syndrome of Parkinson’s disease: A key to explain body schema perception deficit?
  66. Different z-score cut-offs for striatal binding ratio (SBR) of DaT SPECT are needed to support the diagnosis of Parkinson’s Disease (PD) and dementia with Lewy bodies (DLB)
  67. Compressed sensing (CS) MP2RAGE versus standard MPRAGE: A comparison of derived brain volume measurements
  68. Cognitive and Brain Metabolism Profiles of Mild Cognitive Impairment in Prodromal Alpha-Synucleinopathy
  69. European consensus for the diagnosis of MCI and mild dementia: Preparatory phase
  70. Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder
  71. A case of Huntington disease‐like 2 in a patient of African ancestry: the everlasting support of clinical examination in the molecular era
  72. The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson’s Disease
  73. Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments
  74. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease
  75. Epileptic phenotypes in autoimmune encephalitis: from acute symptomatic seizures to autoimmune-associated epilepsy
  76. Case Report: Post-COVID-19 Vaccine Recurrence of Guillain–Barré Syndrome Following an Antecedent Parainfectious COVID-19–Related GBS
  77. Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease
  78. Neurological long-COVID in the outpatient clinic: Two subtypes, two courses
  79. The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort
  80. Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data
  81. The Role of Hub and Spoke Regions in Theory of Mind in Early Alzheimer’s Disease and Frontotemporal Dementia
  82. Case 4: Parkinson’s Disease with Onset as Mild Cognitive Impairment (MCI)
  83. Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer’s disease
  84. Polysomnographic correlates of sleep disturbances in de novo, drug naïve Parkinson’s Disease
  85. Stratification Tools for Disease‐Modifying Trials in Prodromal Synucleinopathy
  86. Abnormal sweating and “skin flushing” as possible predictive factor for treatment related fluctuations in Guillain-Barré syndrome: a case series and a review of the literature
  87. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration
  88. A case series of parainfectious Guillain-Barré syndrome linked to influenza A (H1N1) virus infection
  89. Dopaminergic and Serotonergic Degeneration and Cortical [ 18 F ]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease
  90. Brain Metabolic Correlates of Persistent Olfactory Dysfunction after SARS-Cov2 Infection
  91. FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration
  92. Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients
  93. Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer’s Disease (MCI-AD)
  94. Sex differences in neuroimaging biomarkers in healthy subjects and dementia
  95. Rapid eye movement sleep behavior disorder: A proof‐of‐concept neuroprotection study for prodromal synucleinopathies
  96. Striatal dopamine transporter SPECT quantification: head-to-head comparison between two three-dimensional automatic tools
  97. Neuroimaging Findings in Mild Cognitive Impairment
  98. Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease
  99. The role of anterior prefrontal cortex in prospective memory: an exploratory FDG-PET study in early Alzheimer's disease
  100. Utility of quantitative EEG in early Lewy body disease
  101. Bendamustine–rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy
  102. Brain Aging, Cardiovascular Diseases, Mixed Dementia, and Frailty in the Oldest Old: From Brain Phenotype to Clinical Expression
  103. Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study
  104. Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study
  105. The fate of patients with REM sleep behavior disorder and mild cognitive impairment
  106. Clinical and MRI Predictors of Conversion From Mild Behavioural Impairment to Dementia
  107. Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years
  108. Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer’s Disease and Inconclusive First Biomarker
  109. Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study
  110. Serum neurofilament light chain rate of change in Alzheimer’s disease: potentials applications and notes of caution
  111. Could arterial spin labelling perfusion imaging uncover the invisible in N ‐methyl‐ d ‐aspartate receptor encephalitis?
  112. Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI
  113. Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer’s Disease
  114. 18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease
  115. Increased incidence of axonal Guillain‐Barré syndrome in La Spezia area of Italy: A 13‐year follow‐up study
  116. N-methyl-d-aspartate receptor antibody-related pathologies and pre-existent mental state disorders
  117. Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease
  118. Getting the high school diploma with only one hemisphere: a case report
  119. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD)
  120. Spinocerebellar ataxia 17: full phenotype in a 41 CAG/CAA repeats carrier
  121. Machine Learning Based Analysis of FDG-PET Image Data for the Diagnosis of Neurodegenerative Diseases
  122. Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers
  123. Clinical utility and research frontiers of neuroimaging in movement disorders